Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Strand Therapeutics Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT06249048
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸NextGen Oncology, Beverly Hills, California, United States
© Copyright 2025. All Rights Reserved by MedPath